Real-World Clinical Characteristics And Treatment Of Advanced Non-Small Cell Lung Cancer (Nsclc) Patients In China

e21187 Background: Lung cancer is the leading cause of cancer related mortality worldwide. Approximately 85% of lung cancer is Non-Small Cell Lung Cancer (NSCLC). The clinical profiles and routine practice of advanced NSCLC in China have yet to be described. Methods: This is a multicenter, prospective non-interventional study enrolling and following adult patients who were newly diagnosed with unresectable Stage IIIB or IV NSCLC and received first-line systemic therapy between June, 2015 and October, 2017 in multiple regions in China, to describe the patient journey in terms of diagnosis, treatment, and clinical outcomes. Patient and disease characteristics were analyzed, treatment distribution and duration was evaluated. If in time, survival data will be presented. Results: Overall 1324 patients met the eligibility criteria and were included in the analysis. Median age was 60 years; 65.1% were male; 44.0% were non-smokers; 74.0% were adenocarcinoma, 21.5% were squamous cell carcinoma. The epidermal growth factor receptor (EGFR) mutation testing rate was 44.3% (587/1324). Among patients tested for EGFR, EGFR mutation (EGFRmut) rate was 48.7% (286/587) and among those mutations 87.4%(250/286) were del 19 or exon 21 mutations. Patients with EGFRmut NSCLC were more likely to be female, non-smoker, with stage IV non-squamous tumors. A total of 1101 (83.2%) patients received first line chemotherapy, and 402 (30.4%) patients received first line targeted therapy. Among 286 patients with EGFRmut NSCLC, majority (67.1%) patients received an EGFR tyrosine kinase inhibitor (TKI), with a longer median treatment duration (11.8 months) compared to those receiving chemotherapy (3.7 months) in the first line setting. Conclusions: Our data show that the characteristics of Chinese advanced NSCLC patients, including their EGFR testing and mutation rates, were generally consistent with previous reports. Majority EGFRmut advanced NSCLC patients received an EGFR TKI, and the duration of first line EGFR TKI was longer than that of chemotherapy for EGFRmut patients in this study. Clinical trial information: NCT02458651.